Real-world study of medications for vascular anomalies
Part of Genetic & congenital, Heart & circulation clinical trials.
This study looks at how patients with vascular anomalies (abnormal blood vessel growths) respond to certain medications. It aims to gather real-world information about their care to improve future treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a vascular anomaly (a condition involving abnormal blood vessels or lymph vessels).
- You have been treated with one of the following types of medication for at least 3 months: mTOR inhibitors, MEK inhibitors, or PI3K inhibitors.
- You do not have other rare genetic syndromes that complicate your health.
- You have not been taking many other systemic medications that might make data collection difficult.
- You have not used immunosuppressive drugs (medications that suppress the immune system) frequently, such as systemic steroids.
- You are not currently enrolled in another clinical trial that involves an experimental treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted medicines for people with certain types of vascular malformations (abnormal blood vessels). If you have a slow-flow malformation, you may receive alpelisib; if you have a fast-flow malformation, you may receive mirdametinib. Genetic testing is needed to see if your malformation has a specific change that these drugs target.
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
This trial tests the drug everolimus for people with certain types of vascular anomalies (tumors or malformations in blood vessels) that have not improved with other treatments. It aims to see if everolimus can help shrink these growths or control their symptoms.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This study collects extra blood (and sometimes tissue during procedures) to look for markers that can help doctors better understand vascular anomalies. It may not be a treatment, but it can improve future care by finding patterns linked to the condition.
Hear when a new Vascular Anomalies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.